Why retatrutide has no legal compounded price

Retatrutide is drawing enormous interest, but under US federal law it cannot be legally compounded. Here is what that means for anything sold as compounded retatrutide.

Retatrutide is an investigational triple-agonist weight-loss drug from Eli Lilly. Clinical trial results have been striking, and coverage in outlets like Scientific American has driven consumer demand well ahead of availability.

Here is the constraint that changes the pricing picture: retatrutide is only available through Lilly-sponsored clinical trials. It is not FDA-approved, and under federal law it cannot be legally compounded. Any product sold online as compounded or "research" retatrutide sits outside the licensed pharmacy system.

We track retatrutide as a drug because people search for it, and its monograph states this status plainly. But readers should understand that a published price for compounded retatrutide does not indicate a legal, regulated pathway exists.

This article is general information, not medical advice, and The Peptide Foundation does not sell or prescribe any treatment. Most of these compounds are investigational and not FDA-approved. Talk to a licensed clinician about what is appropriate for you.